Faculty Information - KONDOU Tsunenori

（Last updated : 2026-09-01 10:34:21）

KONDOU Tsunenori
Department School of Medicine(Tokyo Women's Medical University Adachi Medical Center), School of Medicine

Position Professor

■ Books

1.	Chapter contribution	The role of lymphadenectomy in the management of urothelial carcinoma of the upper urinary tract., Upper Tract Urothelial Carcinoma 2015
2.	Chapter contribution	The role of lymphadenectomy in the management of urothelial carcinoma of the upper urinary tract., Upper Tract Urothelial Carcinoma 2014/05

■ Published papers

1.	Original article	Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
2.	Original article	Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
3.	Other	Association of serum kidney injury molecule-1 (KIM-1)with treatment response and survival in metastaticrenal cell carcinoma. 2026/05
4.	Other	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. 2026/05
5.	Other	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. 2026/05
6.	Other	Prognostic impact of early C-reactive proteindynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. 2026/05
7.	Other	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN. 2026/05
8.	Other	Who truly needs adjuvant therapy? A simple clinicopathologic model identifying real candidates for keynote-564-defined intermediate-high-risk clear cell renal cell carcinoma. 2026/05
9.	Original article	Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
10.	Original article	Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
11.	Original article	Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations. 2026/03
12.	Original article	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2026/02
13.	Original article	Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
14.	Original article	Treatment profile of first-line immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma in patients with end-stage renal disease on dialysis. 2026/01
15.	Original article	Renal function with enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan. 2025/12
16.	Original article	Editorial Comment to Impact of Prolonged Warm Ischemia During Clamped Partial Nephrectomy: Comparison Between Japanese and American Cohorts. 2025/11
17.	Original article	Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
18.	Original article	Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinoma. 2025/10
19.	Original article	A case of complete remission of bilateral upper tract carcinoma in situ following retrograde bacillus calmette–guérin (BCG) instillation via open- ended ureteral catheters after failure using Double- J stents. 2025/09/17
20.	Original article	Extended follow-up of robot-assisted partial nephrectomy for renal hilar tumor: A prospective multi-institutional study. 2025/09
21.	Original article	Impact of polypharmacy on perioperative outcomes of robot‐assisted laparoscopic partial nephrectomy for small renal masses. 2025/09
22.	Original article	Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
23.	Original article	Outcomes of enfortumab vedotin treatment in patients ineligible for the EV‐301 trial. 2025/09
24.	Original article	Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
25.	Original article	Genome-wide transcriptome and DNA methylome profiling of acquired cystic disease-associated renal cell carcinoma. 2025/06
26.	Other	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. 2025/05
27.	Other	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. 2025/05
28.	Other	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2025/05
29.	Other	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2025/05
30.	Other	Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial. 2025/05
31.	Original article	Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
32.	Original article	Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan. 2025/04
33.	Case report	Whole exome sequencing identified mutations of forkhead box I 1 (FOXI1), keratin 6 C (KRT6C) and gap junction protein delta 2 (GJD2) in a low-grade oncocytic tumor of the kidney: a case report. 2025/02
34.	Original article	Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. 2025/01/03
35.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
36.	Original article	Impact of tumor dissecting technique on trifecta achievement in patients requiring extended warm ischemia during robot-assisted partial nephrectomy. 2024/10/18
37.	Original article	Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis. 2024/10
38.	Original article	Efficacy of robot-assisted partial nephrectomy compared to conventional laparoscopic partial nephrectomy for completely endophytic renal tumor: a multicenter, prospective study. 2024/10
39.	Original article	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/09
40.	Other	Reply to: Sebastiano Buti and Giulia Claire Giudice’s letter to the editor Re: Comparing a part to the whole—beware of the disparity of the renal cell carcinoma prognostic models. 2024/09
41.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
42.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
43.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
44.	Other	ASO author refections: Recurrence risk prediction in high‑risk renal cell carcinoma: Where We Stand. 2024/05
45.	Original article	Predicting recurrence after radical surgery for high‑risk renal cell carcinoma: Development and internal validation of the “TOWARDS” score. 2024/05
46.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
47.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
48.	Original article	Surgical and functional outcomes of repeat robot-assisted laparoscopic partial nephrectomy compared with repeat open partial nephrectomy. 2024/04
49.	Original article	Comparisons of survival and surgical outcomes between minimally invasive partial nephrectomy and radical nephrectomy in elderly patients with stage 1 renal cell carcinoma. 2024/03
50.	Original article	Prognostic value of the lung immune prognostic index on recurrence after radical surgery for high-risk renal cell carcinoma. 2024/02/14
51.	Original article	Predictive factors and oncological outcomes of pathological T3a upstaging in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. 2024/02
52.	Original article	Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. 2024/01
53.	Original article	A retrospective cohort study of the impact of peripheral blood gamma- delta T cells to prognosis of nonmetastatic renal cell cancer after curative resection. 2023/12
54.	Original article	Effects of remote ischemic preconditioning on renal protection in patients undergoing robot-assisted laparoscopic partial nephrectomy. 2023/10
55.	Original article	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
56.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
57.	Original article	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. 2023/07
58.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/06
59.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
60.	Original article	Impact of warm ischemia on acute kidney injury after robotic partial nephrectomy stratified by baseline kidney function. 2023/03
61.	Original article	Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma. 2023/02
62.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
63.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
64.	Original article	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
65.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
66.	Original article	New longitudinal component of the RENAL nephrometry score for predicting the operative complexity in transperitoneal robot-assisted partial nephrectomy. 2022/06
67.	Original article	Surgical outcomes of robot-assisted laparoscopic partial nephrectomy for cystic renal cell carcinoma. 2022/06
68.	Original article	Prognostic impact of trial-eligibility criteria in patients with metastatic renal cell carcinoma. 2022/04
69.	Original article	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
70.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
71.	Original article	Assessment of Feasibility of Robot-assistted Radical Cystectomy in Patients With Advanced Bladder Cancer Treated With Maintenance Hemodialysis Therapy 2022
72.	Original article	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma 2021/12
73.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
74.	Original article	Comparison of surgical outcomes between enucleation and standard resection in robot-assisted partial nephrectomy for completely endophytic renal tumors through a 1:1 propensity score-matched analysis. 2021/12
75.	Original article	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. 2021/12
76.	Original article	Limited impact of warm ischemic threshold for partial nephrectomy in the robotic surgery era: A propensity score matching study. 2021/12
77.	Original article	Association between ureteral clamping time and acute kidney injury during robot-assisted radical cystectomy. 2021/11
78.	Original article	Three cases of nivolumab plus ipilimumab therapy in haemodialysis patients with metastatic renal cell carcinoma. 2021/11
79.	Original article	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. 2021/10
80.	Original article	Greater renal function benefit from enucleation technique for more complex renal tumors in robot-assisted partial nephrectomy. 2021/10
81.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
82.	Original article	Surgery for renal cell carcinoma extending to the right atrium in Japanese institutions: Focusing on cardiopulmonary bypass with or without deep hypothermic circulatory arrest. 2021/10
83.	Original article	Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. 2021/10
84.	Original article	Albumin-to-alkaline phosphatase ratio as a novel prognostic marker of nivolumab monotherapy for previously treated metastatic renal cell carcinoma. 2021/09
85.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
86.	Original article	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. 2021/06
87.	Original article	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. 2021/05
88.	Original article	Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma. 2021/05
89.	Original article	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. 2021/04
90.	Original article	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. 2021/04
91.	Original article	Therapeutic benefit of lymphadenectomy for older patients with urothelial carcinoma of the upper urinary tract: a propensity score matching study. 2021/04
92.	Original article	Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. 2021/03
93.	Original article	Predictive role of γ‑glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. 2021/03
94.	Original article	The controlling nutritional status CONUT score in patients with advanced bladder cancer after radical cystectomy. 2021/03
95.	Original article	Comparisons of surgical outcomes between transperitoneal and retroperitoneal approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: a propensity score-matched comparative analysis. 2021/02
96.	Original article	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoing robot‑assisted partial nephrectomy using enhanced MDCT. 2021/01
97.	Original article	Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. 2021/01
98.	Original article	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. 2021/01
99.	Original article	Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture: overlapped pathological features among papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, and unclassified RCC. Lessons from a Japanese multicenter study. 2020/11
100.	Original article	Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end‐stage renal disease. 2020/11
101.	Original article	Mid-term outcome of transarterial embolization of renal artery pseudoaneurysm and arteriovenous fistula after partial nephrectomy screened by early postoperative contrast-enhanced CT. 2020/09
102.	Original article	Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era? 2020/08
103.	Original article	Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. 2020/08
104.	Original article	Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. 2020/08
105.	Original article	Lower Incidence of Postoperative Acute Kidney Injury in Robot-Assisted Partial Nephrectomy Than in Open Partial Nephrectomy: A Propensity Score-Matched Study. 2020/07
106.	Original article	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy of a solitary kidney. 2020/06
107.	Original article	The de ritis (aspartate transaminase/alanine transaminase) ratio as a prognosticator in patients with end-stage renal disease-associated renal cell carcinoma. 2020/06
108.	Original article	Efficacy of axitinib after nivolumab failure in metastatic renal cell carcinoma. 2020/05
109.	Original article	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. 2020/05
110.	Original article	Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. 2020/05
111.	Original article	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. 2020/05
112.	Original article	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/04
113.	Other	Editorial Comment to Inflammatory markers for predicting responses to nivolumab in patients with metastatic renal cell carcinoma. 2020/04
114.	Case report	Robot-Assisted Radical Cystectomy With Orthotopic Neobladder as a Urinary Diversion for a Kidney Transplant Recipient: A Case Report. 2020/03
115.	Original article	Computed tomography imaging characteristics of clear cell papillary renal cell carcinoma. 2020/01
116.	Review article	Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma. 2019/12
117.	Original article	Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: Case series of eight patients. 2019/11
118.	Original article	Negative effect of immediate sunitinib interruption on survival in patients with metastatic renal cell carcinoma. 2019/11
119.	Other	Editorial Comment. 2019/10
120.	Original article	Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. 2019/10
121.	Case report	Multiple myeloma with testicular involvement: A case report. 2019/09
122.	Original article	Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. 2019/09
123.	Original article	Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions. 2019/08
124.	Original article	Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program. 2019/08
125.	Original article	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. 2019/08
126.	Original article	RBM10 - TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart florescence in-situ hybridisation: study of 10 cases and a literature review. 2019/08
127.	Original article	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers. 2019/08
128.	Original article	Association between tumor contact surface area and parenchymal volume change in robot-assisted laparoscopic partial nephrectomy carried out using the enucleation technique. 2019/07
129.	Original article	Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer. 2019/07
130.	Original article	Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer. 2019/07
131.	Original article	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/06
132.	Original article	Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. 2019/06
133.	Original article	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. 2019/06
134.	Original article	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/04
135.	Original article	Peritumoral pseudocapsule status according to pathological characteristics from robot-assisted laparoscopic partial nephrectomy for localized renal cell carcinoma. 2019/04
136.	Original article	Prognostic markers for refined stratification of IMDC intermediate-risk metastatic clear cell renal cell carcinoma treated with first-line tyrosine kinase inhibitor therapy. 2019/04
137.	Original article	A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion. 2019/03
138.	Original article	Assessment of postoperative renal function after adrenalectomy in patients with primary aldosteronism. 2019/02
139.	Original article	Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib therapy for metastatic renal cell carcinoma. 2018/12
140.	Original article	Comparative study of lymph node dissection, and oncological outcomes of laparoscopic and open radical nephroureterectomy for patients with urothelial carcinoma of the upper urinary tract undergoing regional lymph node dissection. 2018/11
141.	Original article	Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study. 2018/10
142.	Original article	Follow-up Survey of Donor Candidates for Living Related Kidney Transplantation With Prostate Cancer. 2018/10
143.	Original article	Immediate progressive disease in patients with metastatic renal cell carcinoma treated with nivolumab: a multi-institution retrospective study. 2018/10
144.	Original article	Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy. 2018/10
145.	Original article	Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. 2018/09
146.	Original article	Clinical outocomes in patients with metastatc papillary renal cell carcinoma: A multi-institutional study in Japan. 2018/08
147.	Original article	Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. 2018/07
148.	Original article	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. 2018/06
149.	Original article	Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. 2018/06
150.	Original article	Prognostic impact of the components of progressive disease on survival after first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2018/06
151.	Original article	A case of unilateral nephrectomy performed for autosomal dominant polycystic kidney disease with marked unilateral enlargement. 2018/05
152.	Original article	Response to cao et al. re: Comparison of surgical outcomes between resection and enucleation in robot-assisted laparoscopic partial nephrectomy for renal tumors according to the surface-intermediate-base margin score: A propensity score-matched study. 2018/04
153.	Original article	Robot-assisted laparoscopic partial nephrectomy versus laparoscopic partial nephrectomy: A propensity score-matched comparative analysis of surgical outcomes and preserved renal parenchymal volume. 2018/04
154.	Original article	A case of unilateral nephrectomy performed for autosomal dominant polycystic kidney disease with marked unilateral enlargement 2018/01
155.	Original article	Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. 2017/12
156.	Original article	Comparison of perioperative outcomes with or without renorrhaphy during open partial nephrectomy: A propensity score-matched analysis. 2017/12
157.	Original article	Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2017/12
158.	Review article	Pathological Classification of Renal Cell Carcinoma, based on WHO2016 Classification 2017/12
159.	Original article	Impact of preoperative proteinuria on renal functional outcomes after open partial nephrectomy in patients with a solitary kidney. 2017/11
160.	Original article	Molecular diagnosis of lymph node metastasis in patients with upper urinary tract cancer who underwent lymphadenectomy. 2017/11
161.	Original article	Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. 2017/09
162.	Original article	Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. 2017/09
163.	Original article	Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. 2017/09
164.	Case report	Evaluation of first-line sorafenib treatment for metastatic renal cell carcinoma in kidney transplant patients: A single-center experience with four cases. 2017/08
165.	Original article	Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma. 2017/08
166.	Original article	Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma. 2017/07
167.	Original article	Robot-assisted laparoscopic versus open partial nephrectomy in patients with chronic kidney disease: A propensity score-matched comparative analysis of surgical outcomes. 2017/07
168.	Case report	A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy. 2017/05
169.	Original article	Evaluation of renal cell carcinoma histological subtype and fuhrman grade using (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography. 2017/05
170.	Original article	Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. 2017/03
171.	Original article	Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. 2017/02
172.	Original article	Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. 2017/02
173.	Original article	Surgical and Oncologic Outcomes of Laparoscopic Radical Nephrectomy for Non-Metastatic Renal Cancer in Long-Term Dialysis Patients. 2017/02
174.	Original article	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. 2017/02
175.	Original article	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. 2017/02
176.	Original article	Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802. 2017/01
177.	Original article	Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Renal Cell Carcinoma. 2017/01
178.	Original article	A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell carcinoma: a retrospective non-randomized observational study of initial outcomes. 2016/10
179.	Original article	Sarcopenia and the modified glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment. 2016/10
180.	Original article	Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease. 2016/09
181.	Original article	Late recurrence of a malignant hypoglycemia-inducing pelvic solitary fibrous tumor secreting high-molecular-weight insulin-like growth factor-II: A case report with protein analysis. 2016/07
182.	Original article	Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience with four cases. 2016/07
183.	Original article	Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma. 2016/06
184.	Original article	Comparison of survival rates in stage 1 renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution: a propensity score matching study. 2016/06
185.	Original article	The magnitude of best tumor shrinkage during second-line targeted therapy affects progressionfree survival but not overall survival in patients with metastatic renal cell carcinoma. 2016/06
186.	Original article	Efficacy and feasibility of low-dose rate brachytherapy for prostate cancer in renal transplant recipients. 2016/04/01
187.	Original article	Robot-assisted radical prostatectomy for localized prostate cancer in asian renal transplant recipients. 2016/04
188.	Original article	The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma. 2016/03
189.	Original article	Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. 2016/02
190.	Original article	The safety and validity of surgical resection for hemodialysis-dependent patients with renal cell carcinomas involving the inferior vena cava 2016/02
191.	Original article	Early unclamping might reduce the risk of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. 2015/12
192.	Original article	Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract. 2015/12
193.	Original article	Editorial comment to impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese urological association multi-institutional national database. 2015/11
194.	Other	Possible impact of continuous drainage after minimally invasive partial nephrectomy. 2015/11
195.	Original article	Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population. 2015/10
196.	Original article	Assessment of surgical outcomes of the non-renorrhaphy technique in open partial nephrectomy for ≥T1b renal tumors. 2015/09
197.	Case report	Fat-poor angiomyolipoma with cyst-like changes mimicking a cystic renal cell carcinoma: a case report. 2015/08
198.	Original article	Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era. 2015/08
199.	Case report	Combination of molecular targeted therapy and surgery for a patient with metastatic renal cell carcinoma with a poor prognosis. 2015/07
200.	Original article	Early postoperative screening by contrast-enhanced CT and prophylactic embolization of detected pseudoaneurysms prevents delayed hemorrhage after partial nephrectomy. 2015/07
201.	Review article	Pathology o Renal Cell Carcinoma 2015/06
202.	Original article	Renal sinus exposure as an independent factor predicting asymptomatic unruptured pseudoaneurysm formation detected in the early postoperative period after minimally invasive partial nephrectomy. 2015/04
203.	Original article	Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib. 2015/03
204.	Original article	High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer. 2015/02
205.	Original article	Possible role of template-based lymphadenectomy in reducing the risk of regional node recurrence after nephroureterectomy in patients with renal pelvic cancer. 2014/12
206.	Original article	Clinical symptoms predict poor overall survival in chronic-dialysis patients with renal cell carcinoma associated with end-stage renal disease. 2014/11
207.	Case report	FDG-PET/CT and CT Findings of a Benign solitary Fibrous Tumor of the Kidney; Correlation with Pathology 2014/11
208.	Original article	Enhanced computed tomography after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm. 2014/09
209.	Original article	Cytoreductive nephrectomy for metastatic renal cell carcinoma:A population-based analysis of perioperative outcomes according to clinical stage. 2014/08
210.	Original article	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with pre-existing chronic kidney disease. 2014/06
211.	Original article	Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study. 2014/05
212.	Original article	Stage migration of renal cell carcinoma at a single Japanese university hospital: 24-year study. 2014/04
213.	Case report	Cystic local recurrence of renal cell carcinoma after laparoscopic radical nephrectomy in a hemodialysis patient. 2014/03
214.	Original article	Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma-Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off 2014/03
215.	Original article	Mannitol has no impact on renal function after open partial nephrectomy in solitary kidneys 2014/02
216.	Original article	The influence of RENAL nephrometry score on pre-ruptured pseudoaneurysm formation detected by computed tomography angiography in early postoperative period after minimally invasive partial nephrectomy. 2014/01
217.	Original article	The utility of monitoring serum KL-6 level for predicting the onset of mTOR inhibitors induced interstitial lung disease 2013/07
218.	Original article	Comparison of Survival Rates in Patients with Metastatic Renal Cell Carcinoma According to Treatment Era Including Cytokine and Targeted Therapy 2013/04
219.	Original article	Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: Single-center experience 2013
220.	Original article	Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma 2012/11
221.	Original article	Cytoreductive nephrectomy for pT3b-T4 M1 renal cell carcinoma in 39 patients: single center analysis 2012/09
222.	Original article	Predictors for postoperative renal function after open partial nephrectomy: Including postoperative biomarkers 2012/09
223.	Review article	Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract 2012/04
224.	Original article	Impact of the tumor enhancement pattern in computed tomography for the differential diagnosis of renal cell carcinoma and benign renal tumor 2011/12
225.	Original article	Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: Bilateral occurrence does not influence cancer-specific survival 2011/12
226.	Original article	Decompressive surgery in combination with preoperative transcatheter arterial embolization: Successful improvement of ambulatory function in renal cell carcinoma patients with metastatic extradural spinal cord compression 2011/10
227.	Original article	Analysis of laparoscopic radical nephrectomy for renal cell carcinoma patients with end stage kidney disease requiring hemodialysis 2011/09
228.	Original article	Postoperative renal function after partial nephrectomy for renal cell carcinoma in patients with pre-existing chronic kidney disease: a comparison with radical nephrectomy 2011/06
229.	Review article	The role of lymph node dissection in the management of urothelial carcinoma of the upper urinary tract 2011/06
230.	Original article	Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center 2011/05
231.	Original article	Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. 2010/12
232.	Original article	Contralateral metachronous tumor occurrence is more frequently associated with distant metastases or postoperative intrarenal recurrence in renal cell carcinoma patients 2010/07
233.	Other	105th American urological Association Annual Meeting. 2010
234.	Original article	Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. 2010
235.	Original article	Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: Impact on patient survival. 2010
236.	Original article	Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience. 2009/03
237.	Original article	Clinical outcome of high-grade non-muscle-invasive bladder cancer: A long-term single center experience 2009
238.	Review article	Authors reply to Minimal impact of cold ischemic time on the development of high stage chronic kidney disease observed long-term after partial nephrectomy 2008/11
239.	Original article	Minimal Effect of Cold Ischemia Time on Progression to Late-Stage Chronic Kidney Disease Observed Long Term After Partial Nephrectomy 2008/11
240.	Original article	A case of renal cell carcinoma with intrahepatic vena caval tumor thrombus successfully managed by surgery in a long-term chronic hemodialysis patient with liver cirrhosis 2008/03
241.	Original article	Impact of the Extent of Regional Lymphadenectomy on the Survival of Patients With Urothelial Carcinoma of the Upper Urinary Tract 2007/10
242.	Original article	Successful testis preservation for bilateral testicular tumors with a new chemotherapy-based protocol: Initial results of three cases 2007/09
243.	Original article	Primary Site and Incidence of Lymph Node Metastases in Urothelial Carcinoma of Upper Urinary Tract 2007/02
244.	Original article	Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response 2006/08
245.	Original article	A case of granular cell tumor of the bladder successfully managed with extraperitoneal laparoscopic surgery 2006/06
Display 5 items
Display all(245)

■ Academic conference presentation

1.	Association of serum kidney injury molecule-1 (KIM-1)with treatment response and survival in metastaticrenal cell carcinoma. （Poster notice，General） 2026/05/18
2.	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice，General） 2026/05/18
3.	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. （Poster notice，General） 2026/05/18
4.	Prognostic impact of early C-reactive protein dynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. （Poster notice，General） 2026/05/18
5.	Who truly needs adjuvant therapy? A simple clinicopathologic model identifying real candidates for keynote-564-defined intermediate-high-risk clear cell renal cell carcinoma. （Poster notice，General） 2026/05/18
6.	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN （Poster notice，General） 2026/05/16
7.	Association of Serum Kidney Injury Molecule-1 with Treatment Response and Survival in Metastatic Renal Cell Carcinoma. （Speech，General） 2026/04/25
8.	Evaluation of PSA levels after prostatic urethral lift. （Speech，General） 2026/04/24
9.	Multicenter study of polypharmacy and perioperative outcomes in robot-assisted laparoscopic radical cystectomy with intracorporeal urinary diversion (ICUD). （Poster notice，General） 2026/04/24
10.	Real world data of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma: Multi-center retrospective study in Japan. （Speech，General） 2026/04/24
11.	Association between obesity and adverse events in nivolumab plus cabozantinib combination therapy for metastatic renal cell carcinoma. （Speech，General） 2026/04/23
12.	Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （Poster notice，General） 2026/04/23
13.	Mid-term real-world outcome of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs for renal cell carcinoma using minimum 3-year follow-up data. （Speech，General） 2026/04/23
14.	Novel peripheral blood immune clustering predicts prognosis and T cell exhaustion in renal cell carcinoma. （Poster notice，General） 2026/04/23
15.	Prognostic impact of early C-reactive protein dynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. （Speech，General） 2026/04/23
16.	Prognostic significance of B Cell and NK cell infiltration in the tumor immune microenvironment of renal cell carcinoma. （Poster notice，General） 2026/04/23
17.	Association of serum kidney injury molecule-1 with treatment response and survival in metastatic renal cell carcinoma. （Poster notice，General） 2026/02/28
18.	Immunological clustering from peripheral blood to define prognosis and T cell exhaustion profiles in renal cell carcinoma. （Poster notice，General） 2026/02/28
19.	Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
20.	Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial. （Poster notice，General） 2025/04/29
21.	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. （Poster notice，General） 2025/04/28
22.	Impact of cytoreductive nephrectomy on immunecheckpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies formetastatic renal cell carcinoma with primary kidneytumors. （Poster notice，General） 2025/04/28
23.	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. （Poster notice，General） 2025/04/27
24.	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. （Poster notice，General） 2025/04/26
25.	Clinical outcomes of repeat robot-assisted partial nephrectomy compared to repeat open partial nephrectomy. （Speech，General） 2025/03/23
26.	Therapeutic role of lymphadenectomy in upper tract urothelial carcinoma （Speech，General） 2024/10/26
27.	Greater impact of tumor dissecting technique on trifecta achievement in patients requiring extended warm ischemia during robotic-assisted partial nephrectomy. （Poster notice，General） 2024/05/06
28.	Patient and tumor profile differences for early and late recurrences following radical resection for high-risk renal cell carcinoma. （Poster notice，General） 2024/05/05
29.	Prognostic impact of lung immune prognostic index in recurrence after radical surgery for high-risk renal cell carcinoma. （Poster notice，General） 2024/05/05
30.	Predicting recurrence after radical surgery for high-risk renal cell carcinoma: Development and Internal Validation of　“TOWARDS” score. （Poster notice，General） 2024/05/04
31.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （Poster notice，General） 2024/05/03
32.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. （Poster notice） 2024/04/27
33.	Predicting recurrence after radical surgery for high-risk renal cell carcinoma: development and internal validation of "TOWARDS" score. （Poster notice） 2024/04/27
34.	Therapeutic efficacy of Cabozantinib or Axitinib rechallenge for advanced renal cell carcinoma. （Poster notice，General） 2024/04/27
35.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （Poster notice） 2024/04/26
36.	Clinical study of RAPN between RENAL Nephrometry Score 2-2-3-3 and 1-3-3-3. （Poster notice，General） 2024/04/26
37.	Efficiency of IO-IO combination therapy and IO-TKI combination therapy for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice） 2024/04/26
38.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （Poster notice） 2024/04/26
39.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. （Poster notice） 2024/04/26
40.	Comparison of Perioperative Outcomes between Robot-Assisted Laparoscopic Radical Nephroureterectomy and Laparoscopic Radical Nephroureterectomy. （Poster notice） 2024/04/25
41.	Robotic radical nephroureterectomy with lymphadenectomy - Being a standard procedure for advanced upper tract urothelial carcinoma? - （Speech，Special/Invited Lecture） 2024/04/25
42.	The retrospective study of upfront cytoreductive nephrectomy for metastatic renal cell carcinoma. （Poster notice，General） 2024/04/25
43.	Comparisons of surgical outcomes of robot-assisted laparoscopic partial nephrectomy according to reconstruction methods, including single-layer and double-layer renorraphy: Analyses of an experienced surgeon. （Speech，General） 2024/04/08
44.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. （Poster notice，General） 2023/04/29
45.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. （Poster notice，General） 2023/04/29
46.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy： Real-world data from Japanese single high-volume center. （Poster notice，General） 2023/04/29
47.	Validation of predictive model for new baseline renal function after radical nephrectomy or robot-assisted partial nephrectomy in Japanese patients. （Poster notice，General） 2023/04/29
48.	A multicenter prospective single-arm study of RAPN for entirely endophytic renal tumors compared with a historical LPN control (RAPNCET). （Poster notice，General） 2023/04/21
49.	Effect of remote ischemic preconditioning on renal protection in patients undergoing robot-assisted laparoscopic partial nephrectomy. （Poster notice） 2023/04/21
50.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy: Real-world data from Japanese single high-volume center. （Speech，General） 2023/04/21
51.	Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC). A clinicopathological study of 10 Japanese cases. （Poster notice，General） 2023/04/21
52.	Higher risk of intraoperative bleeding in right-sided renal tumors compared to left-sided tumors in robot-assisted partial nephrectomy. （Speech，General） 2023/04/20
53.	Impact of warm ischemia on acute kidney injury after robotic partial nephrectomy stratified by baseline kidney function. （Speech） 2023/04/20
54.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. （Speech，General） 2023/04/20
55.	Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. （Poster notice，General） 2022/05/16
56.	Efficacy and feasibility of robot-assisted partial nephrectomy for octogenarians: Comparison with younger counterparts. （Poster notice，General） 2022/05/15
57.	Order of thrombectomy for management of renal cell carcinoma with inferior vena cava thrombus. （Poster notice，General） 2022/05/15
58.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. （Poster notice，General） 2022/05/13
59.	Association between ureteral clamping time and acute kidney injury during robot-assisted radical cystectomy. （Poster notice，General） 2022/05/13
60.	C-reactive protein kinetics to predict recurrence after radical surgery for high-risk renal cell carcinoma. （Poster notice，General） 2022/05/13
61.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. （Poster notice，General） 2022/05/13
62.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
63.	Predictive impact of early changes in serum c-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
64.	Comparison of surgical outcomes in robot-assisted partial nephrectomy for completely endophytic renal tumors between enucleation and standard resection through a 1:1 propensity score–matched analysis. （Poster notice） 2021/09/12
65.	Medication adherence and treatment outcome in patients with metastatic castration-resistant prostate cancer receiving enzalutamide. （Speech，General） 2020/12/24
66.	Association between controlling nutritional status（CONUT）score and outcomes after radical cystectomy for advanced bladder cancer. （Speech，General） 2020/12/23
67.	Association between early tumor response and survival in metastatic renal cell carcinoma treated with nivolumab. （Speech，General） 2020/12/23
68.	Comparison of efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. （Speech，General） 2020/12/23
69.	Safety and efficacy of nivolumab for patients with chronic kidney disease. （Speech，General） 2020/12/23
70.	The predictive impact of presurgical sarcopenia on patient survival in patients with renal cell carcinoma with inferior vena cava tumor thrombus. （Speech，General） 2020/12/23
71.	Therapeutic benefit of lymphadenectomy during radical nephroureterectomy for elderly patients with upper tract urothelial carcinoma. （Speech，General） 2020/12/23
72.	Reduced risk of new occurrence or progression of sarcopenia by robot-assisted radical cystectomy compared to the open procedure. （Speech，General） 2020/12/22
73.	Trifecta outcomes of robot-assisted laparoscopic partial nephrectomy compared to conventional partial nephrectomy. （Speech，General） 2020/12/22
74.	The 34th Congress of Japanese Society of Endourology （Speech，General） 2020/11/19
75.	Genetic and epigenetic profiling reveals the proximal tubule origin of renal cancers in end-stage renal disease. （Poster notice，General） 2020/10/01
76.	Comparisons of surgical outcomes between transperitoneal and retroperitoneal　approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: A propensity score-matched comparative analysis. （Speech，General） 2020/07/17
77.	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoingrobot-assisted partial nephrectomy, using enhanced CT. （Speech，General） 2020/07/17
78.	Predictive factors for recurrence after complete metastasectomy in patients with metastaticrenal cell carcinoma in the targeted therapy era. （Speech，General） 2020/07/17
79.	Usefulness of robot-assisted laparoscopic partial nephrectomy using trifecta criteria. （Poster notice，General） 2020/07/17
80.	Clinical relevance of immunoglobulin M deposition in peritubular capillaries in ABO-incompatible kidney transplantation. （Poster notice，General） 2020/05/30
81.	The relationship between metformin and post-operative recurrence of renal cell carcinoma （Poster notice，General） 2019/10/24
82.	Renal cell carcinoma in end-stage renal disease exhibits specific molecular alterations corresponding to their histopathology. （Poster notice，General） 2019/10/18
83.	Immunoglobulin deposition in peritubular capillaries in ABO-incompatible kidney Transplantation （Speech，General） 2019/10/02
84.	Clinicopathological study on renal cell carcinoma with tubulocystic architectures. （Poster notice，General） 2019/09/27
85.	Renal cell carcinoma in end-stage renal disease has specific molecular alterations corresponding to the histopathology. （Poster notice，General） 2019/09/27
86.	Renal cell carcinoma with tubulocystic architectures - Clinicopathological study on 5 cases （Poster notice，General） 2019/05/11
87.	Malignant solitary fibrous tumor in the kindney. A case report （Poster notice，General） 2019/05/10
88.	Mixed epithelial and stromal tumor (MEST) in the kidney of the male patient. A case report （Poster notice，General） 2019/05/10
89.	Prostate imaging reporting and data system score before prostate biopsy can predict biochemical recurrence in patients with prostate cancer treated with radiotherapy. （Poster notice，General） 2019/05/06
90.	Association between tumor contact surface area and parenchymal volume change in robot-assisted laparoscopic partial nephrectomy performed using the enucleation technique. （Poster notice，General） 2019/05/04
91.	Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib herapy for metastatic renal cell carcinoma. （Poster notice，General） 2019/05/04
92.	Long-term follow-up of renal function and development of chronic kidney disease after partial nephrectomy. （Poster notice，General） 2019/05/04
93.	Presence of peritumoral pseudocapsules detected based on findings from robot-assisted laparoscopic partial nephrectomy for localized renal cell carcinoma. （Poster notice，General） 2019/05/04
94.	Robot-assisted partial nephrectomy is superior in terms of postopetive acute kidney injury,as compared to open partial nephrectomy （Poster notice，General） 2019/05/04
95.	Association of immune-related adverse events with prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. （Speech，General） 2019/05/03
96.	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoing robot-assisted partial nephrectomy, using enhanced CT. （Poster notice，General） 2019/05/03
97.	Case Management （Speech，Panelist at Symposium/Workshop (Appointed)） 2019/02/07
98.	Role of immunotherapy in UC （Speech，Panelist at Symposium/Workshop (Appointed)） 2019/01/12
99.	Immunotherapy for metastatic renal cell carcinoma （Speech，Panelist at Symposium/Workshop (Appointed)） 2019/01/11
100.	Robotic surgeries for urological malignancies in renal transplant recipients （Speech，Special/Invited Lecture） 2018/10/05
101.	Safety and impact on renal function of nivolumab use for patients with chronic kidney disease and end stage renal disease in metastatic renal cell carcinoma. （Speech，General） 2018/08/18
102.	Immunotherapy in GU cancer:current trends and future perpectives （Speech，Special/Invited Lecture） 2018/06/04
103.	Effect of luteinizing hormone-eleasing hormone antagonist on testosterone recovery after neoadjuvant therapy with or without adjuvant androgen deprivation and radiotherapy for localized prostate cancer. （Poster notice，General） 2018/05/21
104.	Superior efficacy of degarelix as neoadjuvant hormone therapy in control of acute genitourinary toxicity associated with radiation therapy for prostate cancer compared to LHRH agonist; A propensity-score matching analysis. （Poster notice，General） 2018/05/21
105.	Clinicopathological analysis of prostate cancer in patients with renal transplant recipients. （Poster notice，General） 2018/05/20
106.	Effect of early-period relative dose intensity in first-line sunitinib therapy with a 2-weeks-on and 1-week-off regimen for metastatic renal cell carcinoma. （Poster notice，General） 2018/05/20
107.	Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. （Poster notice，General） 2018/05/20
108.	Comparison of kidney function in the early postoperative period between a transperitoneal versus retroperitoneal robot-assisted laparoscopic partial nephrectomy for posterior renal tumor : A propensity score-matched study. （Poster notice，General） 2018/05/19
109.	Prognostic value of the glasgow Prognostic score for patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. （Poster notice，General） 2018/05/19
110.	Current treatment strategy of mRCC patients （Speech，Panelist at Symposium/Workshop (Appointed)） 2018/05/18
111.	Predictive factors for immediate progression after nivolumab therapy for metastatic renal cell carcinoma. （Speech，General） 2018/04/20
112.	Adaptor protein CRK regulates ErbB2 expression in exosome and promotes tumor progression and metastasis of bladder cancer. （Poster notice） 2018/04/19
113.	Usefulness of the modified Glasgow Prognostic Score (mGPS) in patients with castration- sensitive prostate cancer: muti- institutional study. （Poster notice） 2018/04/19
114.	Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with renal cell carcinoma. （Poster notice，General） 2018/04/18
115.	Effect of ABO blood type on the outcomes of metastatic renal cell carcinoma patients treated with first-line tyrosine kinase inhibitors. （Poster notice，General） 2018/04/18
116.	How do immune checkpoint inhibitors change the treatment strategy for mRCC patients in Japan? （Speech，Panelist at Symposium/Workshop (Appointed)） 2018/04/05
117.	How to Optimize Clinical Benefit of Sunitinib in mRCC Patients Facing Challenges in the Real World Practice （Speech，Special/Invited Lecture） 2018/03/31
118.	Redical Prostatectomy for Localized Prostate Cancer in Renal Transplant Recipients:13 Cases Studied at a Single Center （Poster notice，General） 2017/11/28
119.	Pathological Classification of Renal Cell Carcinoma, based on WHO2016 （Speech，Panelist at Symposium/Workshop (Appointed)） 2017/10/21
120.	Optimizing Excision and Reconstruction （Speech，General） 2017/10/20
121.	Prostate imaging reporting and data system score before prostate biopsy can predict biochemical recurrence in patients with prostate cancer treated with radiotherapy. （Speech，General） 2017/08/19
122.	Robot-Assisted Partial Nephrectomy -How Can We Safely Expand Indication? （Speech，Special/Invited Lecture） 2017/08/19
123.	Evaluation of renal cell carcinoma histological subtype and fuhrman grade using (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography. （Poster notice，General） 2017/06/12
124.	Higher risk of recurrence at extraregional nodes after radical nephroureterectomy in patients with left than in patients with right ureteral cancer （Speech，General） 2017/05/15
125.	Analysis of predictive factors associated with prolonged operative time during robot-assisted partial nephrectomy （Poster notice，General） 2017/05/14
126.	Clinicopathological characteristics of patients with acquiredcystic disease-associated renal cell carcinoma: Central pathology results according to the 2016 WHO classification in a multi-institutional study （Speech） 2017/05/14
127.	The Superior Preservation of Postoperative Renal Function in Robotic Partial Nephrectomy,Compared with the Laparoscopic Procedure,is Associated with Less Parenchymal Volume Loss,Not Shorter Renal Ischemia Time:A Propensity Score-Matched Analysis （Poster notice，General） 2017/05/14
128.	FH-deficient RCC with a Tubulocystic RCC-like morphology.A case report （Poster notice，General） 2017/04/27
129.	Clinicopathological characteristics of the patients with acquired-cystic disease-associated renal cell carcinoma according to 2016 WHO classification. （Poster notice，General） 2017/04/21
130.	Usefulness of multiparametric MRI in prognosis for high risk prostate cancer after radiotherapy. （Poster notice，General） 2017/04/21
131.	Robot-Assisted Partial Nephrectomy - How Can We Epand Indication?- （Speech） 2017/02/18
132.	Impact of surgeon's experience on occurrence of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. （Poster notice，General） 2016/11/11
133.	Comparison of surgical and oncologic outcomes between long-term and short-term dialysis patients undergoing laparoscopic radical nephrectomy for non-metastatic renal cancer. （Poster notice，General） 2016/11/09
134.	Efficacy and feasibility of radiotherapy for localized prostate cancer in renal transplant recipients: a single-center experience. （Poster notice，General） 2016/08/20
135.	Current status of systemic therapy for metastatic renal cell carcinoma. （Speech） 2016/07/09
136.	Postoperative rebound of anti-blood type antibodies and antibody-mediated rejection after ABO-incompatible living related kidney transplantation - Is prophylactic treatment necessary? （Poster notice，General） 2016/06/13
137.	Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative FDG-PET/CT in Patients with Renal Cell Caercinoma （Poster notice，General） 2016/06/13
138.	Risk factors for asymptomatic renal artery pseudoaneurysm after partial nephrectomy detected by enhanced CT in the early postoperative period. （Poster notice，General） 2016/05/09
139.	Assessment of surgical outcomes of the non-renorrhaphy technique in open partial nephrectomy for =T1B renal tumors. （Poster notice，General） 2016/05/08
140.	Association of preoperative proteinuria with renal functional outcomes after open partial nephrectomy in patients with an anatomically or functionally solitary kidney. （Poster notice，General） 2016/05/08
141.	Comparison of perioperative outcomes with or without renorrhaphy in open partial nephrectomy: A propensity score-matched study. （Poster notice，General） 2016/05/08
142.	Preoperative prostate imaging reporting and data system score: An independent predictor of positive surgical margin after robot-assisted radical prostatectomy. （Poster notice，General） 2016/05/08
143.	Sarcopenia and the modified glasgow prognostic score are significant predictors of patient survival in metastatic renal cell carcinoma patients receiving first-line sunitinib treatment. （Poster notice，General） 2016/05/07
144.	Clinical outcomes in patients with metastatic papillary renal cell carcinoma: A Japanese multi-institutional study. （Poster notice，General） 2016/05/06
145.	Prostate imaging reporting and data system score before prostate biopsy can predict biochemical failure in prostate cancer patients treated with high-dose-rate brachytherapy. （Poster notice，General） 2016/05/06
146.	Better preservation of renal function after robotic partial nephrectomy is associated with lower volume loss compared with laparoscopic partial nephrectomy. （Speech） 2016/04/25
147.	Lymphatic metastases from the urothelial carcinoma of the left lower ureter spreads more extensively at higher incidence than the tumors of the right side. （Speech） 2016/04/24
148.	Clinical outcomes in patients with metastatic papillary renal cell carcinoma:A multi-institutional study in Japanese Society of Renal Cancer. （Poster notice，General） 2016/04/23
149.	Comparison of perioperative outcomes with or without renorrhaphy in open partial nephrectomy: A propensity score-matched study. （Poster notice，General） 2016/03/14
150.	Risk factors for asymptomatic renal artery pseudoaneurysm after partial nephrectomy detected by enhanced CT in the early postoperative period. （Poster notice，General） 2016/03/14
151.	Association between better renal function preservation and lower volume loss between robotic partial nephrectomy and laparoscopic partial nephrectomy: A propensity score matched analysis. （Poster notice，General） 2016/03/13
152.	The 2nd symposium on upper tract urothelial carcinoma session lymphadenectomy. （Speech，Panelist at Symposium/Workshop (Other)） 2015/12/02
153.	Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience. （Speech，Panelist at Symposium/Workshop (Other)） 2015/10/30
154.	Early unclamping technique significantly increases the probability of achieving pentafecta after robot-assisted laparoscopic partial nephrectomy. （Poster notice，General） 2015/10/03
155.	endGIA decreased Positive Margin of Apex in Laparoscopic Radical Prostatectomy. （Poster notice，General） 2015/10/02
156.	Efficacy and feasibility of intensity-modulated radiation therapy for prostate cancer in renal-transplant recipients. （Poster notice，General） 2015/08/26
157.	Efficacy and feasibility of low-dose brachytherapy for prostate cancer in renal-transplant recipients. （Poster notice，General） 2015/08/26
158.	Robot-assisted radical prostatectomy in renal transplant recipients: the first report in asian patient. （Poster notice，General） 2015/08/26
159.	The clinical benefit of metastasectomy in metastatic renal cell carcinoma in the era of targeted molecular therapy. （Poster notice，General） 2015/05/18
160.	The relationship between the timing of maximum tumor shrinkage during 1st-line targeted therapy and overall survival of patients with metastatic renal cell carcinoma. （Poster notice，General） 2015/05/18
161.	Comparison of survival rates in stage one renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution. （Poster notice，General） 2015/05/17
162.	Molecular diagnosis of lymph node metastasis in patient with upper urinary tract cancer who had extended lymphadenectomy. （Poster notice，General） 2015/05/15
163.	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence in patients with upper/middle ureteral cancer. （Poster notice，General） 2015/05/15
164.	Management of mRCC in the era of targeted therapy. （Speech，Special/Invited Lecture） 2015/05/04
165.	Management of mRCC in the era of targeted therapy. （Speech，Special/Invited Lecture） 2015/05/03
166.	Management of mRCC in the era of targeted therapy. （Speech，Special/Invited Lecture） 2015/05/02
167.	Improving Outcomes in mRCC by Sequential Therapy （Speech，Special/Invited Lecture） 2014/10/25
168.	Early unclamping technique may reduce therisk of pseudoaneurysm formation detected by computed tomography angiography in the early postoperative period after robot-assisted laparoscopic partial nephrectomy. （Poster notice，General） 2014/09/04
169.	Template-based lymphadenectomy reduced the risk of regional node recurrence in patients with renal pelvic cancer. （Poster notice，General） 2014/05/20
170.	Limited benefit of targeted therapies on ivc thrombus in renal cell carcinoma. （Poster notice，General） 2014/05/19
171.	Perioperative outcomes in cytoreductive nephrectomy for metastatic renal cell carcinoma according to clinical stage: a population-based analyses. （Poster notice，General） 2014/05/19
172.	Risk factors and management of unruptured renal artery pseudoaneurysms immediately after laparoscopic partial Nephrectomy. （Speech，General） 2014/05/19
173.	What is your choice of treatment for upper urinary tract UC? A case discussion. （Speech，Panelist at Symposium/Workshop (Other)） 2014/05/18
174.	High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer. （Poster notice，General） 2014/05/17
175.	Case study 3: Managing TKI-related AEs and utilizing biomarkers to optimize therapy. （Speech，General） 2014/05/10
176.	Determinant therapeutic strategy-targeting the right the pathways and mechanism that matter in 2nd+line mRCC. （Speech，General） 2014/05/10
177.	Panel discussion （Speech，Panelist at Symposium/Workshop (Other)） 2014/05/10
178.	Clinical date on Inlyta and experience from Japanese and Asian date （Speech，Panelist at Symposium/Workshop (Appointed)） 2014/01/25
179.	mRCC Treatment:beyond operation （Speech，General） 2013/12/14
180.	Optimizing Patient Outcomes in Second-Line Treatment and Sequencing of Advanced RCC Therapy （Speech，General） 2013/11/04
181.	Optimizing patient outcomes in 2nd line treatment and sequencing in advanced RCC （Speech，Panelist at Symposium/Workshop (Other)） 2013/11/03
182.	Advantages of transperitoneal approach over retroperitoneal approach in laparoscopic radical nephrectomy for renal cancer in patients with dialysis-dependent, end-stage renal disease （Speech，General） 2013/09/09
183.	Impact Of Preoperative C-Reactive Protein On Survival Of Patients On Chronic Hemodialysis Undergoing Nephrectomy For Renal Cell Carcinoma （Speech，General） 2013/08/31
184.	The Clinical Benefit of Targeted Therapies On IVC Thrombus Of Renal Cell Carcinoma （Speech，General） 2013/08/31
185.	The Role Of Lymphadenectomy in Urothelial Carcinoma Of The Upper Urinary Tract-Pros And Cons- （Speech，Special/Invited Lecture） 2013/08/31
186.	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with pre-existing chronic kidney disease （Poster notice，General） 2013/05/20
187.	Usefulness of temporary inferior vena cava filter in preventing intraoperative pulmonary embolism for patients with renal cell carcinoma extending into inferior vena cava thrombus （Poster notice，General） 2013/05/07
188.	Better kidney functional recovery in patients with de novo CKD after partial nephrectomy compared to those with pre-existing CKD （Speech，General） 2013/05/06
189.	Enhanced CT after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm （Poster notice，General） 2013/05/06
190.	Therapeutic benefit from template-based lymphadenectomy in urothelial carcinoma of the renal pelvis - Multi-institutional prospective study - （Speech，General） 2013/05/06
191.	Therapeutic benefit from template-based lymphadenectomy in urothelial carcinoma of the renal pelvis （Speech，General） 2013/03/18
192.	Three-dimensional MDCT evaluation in patients after partial nephrectomy: prevalence of early post-operative renal artery pseudoaneurysms （Poster notice，General） 2013/03/07
193.	Should mRCC patients undergo surgery? （Speech，Special/Invited Lecture） 2013/03/03
194.	Asian subgroup analysis and real world experiences in Japan （Speech，Special/Invited Lecture） 2013/03/02
195.	Panelist （Speech，Panelist at Symposium/Workshop (Other)） 2013/03/02
196.	Analysis of factors associated with perioperative outcomes in patients with dialysis-dependent end-stage renal disease undergoing laparoscopic radical nephrectomy （Speech，Panelist at Symposium/Workshop (Other)） 2013/02/09
197.	Anatomic complexity quantitated by nephrometry score ssociated with kidney function after partial nephrectomy （Speech，General） 2013/02/08
198.	Partial Nephrectomy for RCC-Current and Future Issues- （Speech，Panelist at Symposium/Workshop (Other)） 2012/10/04
199.	Impact of RENAL nephrometry Score on Renal Function after Partial Nephrectomy in Solitary Kidneys （Speech，General） 2012/10/01
200.	No Impact of Mannitol on Renal Function after Partial Nephrectomy in Solitary Kidneys （Speech，General） 2012/10/01
201.	Safty of Partial Nephrectomy for Patients on Chronic Anticoagulant Therapy （Speech，General） 2012/10/01
202.	Comparison of Survival Rates in Patients with Metastatic Renal Cell Carcinoma According to the ERA Including PRE-Cytokine,Cytokine and Targeted Therapy （Speech，General） 2012/08/18
203.	No Impact of Mannitol on Renal Function after Partial Nephrectomy in Solitary Kidneys （Speech，General） 2012/08/18
204.	Significant Negative Impact of Papillary Histological Subtype in Patients with Renal Cell Carcinoma Extending into the Inferior Vena Cava in Comparison to Clear Cell Subtype:Single-Center Experience （Speech，General） 2012/05/22
205.	Favorable Impact of Routine Screening of kidneys on the Overall Survival of Patients with Renal Cell Carcinoma Associated with End Stage Renal Disease under Chronic Dialysis Therapy （Poster notice，General） 2012/05/21
206.	Predictors for Postoperative Renal Function after Partial Nephrectomy-Including Postoperative Biomarkers （Poster notice，General） 2012/05/21
207.	Renal Cell Carcinoma(RCC) in Patients with End-stage Renal Disease: Does it really exhibit favorable prognosis compared to sporadic RCC? （Poster notice，General） 2012/05/20
208.	Influence of Nephrometry Score on the Incidence of Complication of Laparoscopic Partial Nephrectomy （Speech，General） 2011/12/02
209.	Influence of nephrometry score on the incidence of complication of laparoscpic partial nephrectomy （Speech，General） 2011/11/29
210.	Influence of nephrometry scoring system on the incidence of complication of laparoscpic partial nephrectomy （Speech，General） 2011/11/29
211.	Incidence of lymph node involvement according to pathological T stage or tumor grade in the urothelial carcinoma of the upper urinary tract （Speech，General） 2011/08/13
212.	Prognosis and characteristics of renal cell carcinoma in hemodialysis patients-Comparison between unilateral and bilateral occurrence （Speech，General） 2011/08/13
213.	The increased utilization of partial nephrectomy for patients with renal cell carcinoma with the normal contralateral kidney-the influence of tumor size on the choice surgical procedure in this expert single center （Speech，General） 2011/05/16
214.	No inpact of tumor location on the residual renal function after nephron-sparing surgery in the patients with renal tumors （Speech，General） 2010/11
215.	Greater impact of lymphadenectomy according to the regional node template on the survival of patients with urothelial carcinoma of the upper urinary tract-a comparison between the template and the total number of lymph nodes removed （Speech，General） 2010/05
216.	No impact of tumor location on the residual renal funtion after nephron-sparing surgery in the patients with renal tumors （Speech，General） 2010/05
Display 5 items
Display all(216)

■ Social activities

2018/10

54th Annual Congress of the Japan Society for Transplantation Sponsored Semenar 6(Chair)Molecular targeted therapy in patients with metastatic renal cell carcinoma after kidney transplantation

■ Education

1.		〔Doctoral course〕〔Doctorial Course〕, Graduate School, Division of Medicine, Tokyo Women's Medical University, Completed, Doctor of Philosophy
2.	1984/04～1990/03	Faculty of Medicine, Hokkaido University, Graduated,